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Novel agents such as thalidomide, lenalidomide and bortezomib have dramatically changed the 
treatment paradigm of multiple myeloma (MM). However, it is not clear whether these agents 
improve the prognosis of elderly patients who have undergone autologous stem cell transplantation 
(auto-SCT). We retrospectively analyzed the outcome of 318 newly diagnosed patients aged 65-70 
years who were treated between January 1, 2004, and December 31, 2009. As initial therapy, 192 
patients were treated with conventional chemotherapy, 88 with novel agent-containing regimens, 21 
with conventional chemotherapy plus auto-SCT and the remaining 17 with novel agents plus auto-
SCT. The median progression-free survival was 19.1, 24.5, 26.8 and 35.2 months, respectively, and 
the 5-year overall survival (OS) was 40, 62, 63 and 87%, respectively. Initial therapy with novel 
agents (p < 0.001) or auto-SCT (p < 0.02) significantly improved OS compared with the group 
without these treatment modalities. Salvage therapy with novel agents also significantly improved 
survival after relapse compared with conventional chemotherapy alone (p < 0.04). In a multivariate 
analysis, the use of novel agents was an independent prognostic factor significantly associated with 
extended OS (p < 0.003). These results indicate that novel agents and auto-SCT had a major impact 
on OS in eligible patients in this subgroup of MM. 
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 Introduction 
Multiple myeloma (MM) is a plasma cell neoplasm characterized by the production of monoclonal 
immunoglobulin (Ig) and various clinical features such as hypercalcemia, renal failure, anemia and 
osteolytic bone lesions, as well as immunodeficiency [1]. MM remains incurable; however, the 
response rate, progression-free survival (PFS) and overall survival (OS) have significantly 
improved due to the introduction of initial treatment incorporating novel agents such as 
thalidomide, lenalidomide and bortezomib, and autologous stem cell transplantation (auto-SCT) 
[2,3,4]. Based on the results from randomized phase III studies, the National Comprehensive 
Cancer Network guidelines recommended the use of thalidomide, lenalidomide and bortezomib in 
the treatment of both transplant-eligible and noneligible patients [5,6]. Thus, novel agents have 
become the standard of care for symptomatic MM as primary therapy and salvage therapy. 
Auto-SCT is the standard front-line consolidation therapy, especially for younger patients less than 
65 years of age. In elderly patients more than 65 years old, the efficacy and feasibility of an 
intermediate dose of melphalan (100-140 mg/m
2
) as a conditioning regimen have been reported 
previously [7,8,9]. However, it is not clear whether the combined use of novel agents with auto-
SCT translates into better outcome in elderly patients. 
To clarify this issue, we retrospectively analyzed the clinical features and treatment outcome of 
unselected MM patients aged 65-70 years in the facilities of the Japanese Society of Myeloma and 




Between January 1, 2004, and December 31, 2009, a total of 318 newly diagnosed MM patients 
aged 65-70 years were treated in 39 facilities of the Japanese Society of Myeloma and the European 
Myeloma Network. The diagnosis and clinical staging of MM were based on the Durie-Salmon 
staging system and the International Staging System (ISS) [10,11]. Baseline demographics, clinical 
and laboratory data at diagnosis and information concerning treatment and response were collected 
retrospectively during January 2012 and May 2012. This survey covered unselected patients treated 
at the participating facilities, including several patients who had been enrolled in clinical trials, but 
most patients had been treated in routine practice. This retrospective study was approved by the 
Ethics Committee/Institutional Review Board of Tokushima Prefectural Central Hospital. 
 Treatment 
The primary objective was to assess the outcome of patients treated with different initial therapy. 
Treatment for each patient was determined by the corresponding physician. The short-term use of 
dexamethasone for emergent disease control was not considered conventional chemotherapy. Novel 
agents included thalidomide, lenalidomide and bortezomib in combination with dexamethasone 
and/or chemotherapeutic agents. Auto-SCT was performed as up-front therapy after induction 
therapy by using a high or intermediate dose of melphalan followed by peripheral blood SCT 
according to the institutional protocol. The transplantation-related mortality was defined as death 
due to any cause other than disease progression or relapse within 100 days after transplantation. 
Clinical response was evaluated according to the international uniform response criteria for MM 
[12]. 
 Statistical Analysis 
PFS and OS curves were calculated using the Kaplan-Meier estimate, and differences between the 
curves were evaluated with the log-rank test. The Cox proportional hazards model was used to 
determine independent predictors associated with extended OS. Variables included baseline patient 




A total of 318 patients were studied. There were 167 males and 151 females. The median age was 
67 years (range 65-70). The type of monoclonal Ig was IgG in 169 patients, IgA in 80, light chain in 
56, IgD in 7 and others in 6. Performance status of 0, 1 and ≥2 were found in 88, 96 and 93 patients, 
respectively. Twenty-two patients were classified as Durie-Salmon stage I, 73 as stage II, 216 as 
stage III and 7 as unknown. With regard to the ISS, 86 patients were stage I, 107 stage II and 102 
stage III. Unfortunately, data on cytogenetic abnormalities were not available for most patients. 
As initial therapy, 192 patients were treated with conventional chemotherapy, as follows: melphalan 
+ prednisone in 83, vincristine + adriamycin + dexamethasone in 56, high-dose dexamethasone in 
25 and other regimens in 28, including ranimustine + vindesine + melphalan + prednisone, 
vincristine + melphalan + dexamethasone ± ranimustine, and methyl prednisone + vincristine + 
melphalan + prednisone. Another 88 patients were treated with novel agent-containing regimens 
composed of bortezomib + dexamethasone ± adriamycin in 33 patients, melphalan + prednisone + 
bortezomib in 29, melphalan + prednisone + lenalidomide in 17, and thalidomide + dexamethasone 
or melphalan + prednisone + thalidomide in 9. An additional 21 patients were treated with 
conventional chemotherapy (either vincristine + adriamycin + dexamethasone, melphalan + 
prednisone or high-dose dexamethasone) plus auto-SCT (13 single SCT and 8 tandem SCT), and 
the remaining 17 patients were treated with a novel agent-based regimen (bortezomib and 
dexamethasone) plus auto-SCT (14 single SCT and 3 tandem SCT). As the conditioning regimen 
before auto-SCT, 140 mg/m
2
 melphalan was used in 2 patients in the novel agent group and 200 
mg/m
2
 melphalan was used in the remaining 36 patients. Baseline characteristics according to the 




Table 1. Patient characteristics according to initial therapy 
 
Outcome according to Clinical Stage 
We first assessed PFS and OS according to clinical stage. The median PFS for Durie-Salmon stage 
I, II and III was 40.5, 25.6 and 20.9 months, respectively, and a significant difference was found 
between stages I and III (p < 0.02; fig. 1a). The median OS was 55.2 months for stage III but was 
not reached in either stage I or II. 
  
Fig. 1. Outcome according to clinical stage. a PFS and OS according to Durie-Salmon stage. b PFS and OS 
according to the ISS. 
 
As for ISS stage I, II and III, the median PFS was 31.1, 25.0 and 14.2 months, respectively, and 
significant differences were found between stages I and III (p < 0.00001), and stages II and III (p < 
0.0003; fig. 1b). The median OS was 36.8 months for stage III but was not reached in stages I and 
II. OS was significantly shorter for ISS stage III compared with that for stage I or II (p < 0.00001). 
 Outcome according to Initial Therapy 
We next compared PFS and OS according to initial therapy. The median PFS of the 4 different 
treatment groups, i.e. conventional chemotherapy, novel agents, conventional chemotherapy plus 
auto-SCT and novel agents plus auto-SCT, was 19.1, 24.5, 26.8 and 35.2 months, respectively (fig. 
2a). PFS was significantly improved in patients treated with a novel agent-containing regimen (p < 
0.01) and in those treated with novel agents plus SCT (p < 0.04) compared with that of the patients 
treated with the conventional chemotherapy alone. The median OS of the conventional 
chemotherapy group was 46.0 months, while it was not reached in the other groups. When we 
compared the outcome of the conventional chemotherapy group, there was a significant 
improvement in OS in the following treatment groups: novel agent-containing regimen (p < 0.001), 
chemotherapy plus SCT (p < 0.02) and novel agents plus SCT (p < 0.02). In terms of auto-SCT or 
novel agents as the front-line treatment, the median OS was significantly improved in the auto-SCT 
group compared with the non-SCT group (not reached vs. 57.9 months, p < 0.02) and more so in the 
novel agents group compared with the non-novel agents group (not reached vs. 49.3 months, p < 
0.001; fig. 2b). No transplantation-related mortality was observed. 
 
 
Fig. 2. Outcome according to initial therapy. a PFS and OS according to initial therapy, i.e. either 
conventional chemotherapy, novel agents, conventional chemotherapy plus auto-SCT or novel agents plus 
auto-SCT. b OS of patients treated with first-line auto-SCT or novel agents. 
 Efficacy of Novel Agents on OS 
Because the induction therapy with novel agents had a significant impact on OS, we further 
evaluated the impact of novel agents as salvage therapy. When we analyzed OS in terms of the use 
of novel agents, the median OS was significantly improved in the group of patients treated with 
novel agents either as first-line or salvage therapy (second- and third-line) compared with those 
treated with conventional chemotherapy alone [86.7 months (n = 232) vs. 38.0 months (n = 86), p < 
0.0001; fig. 3a]. Among 168 relapsed patients who received either conventional chemotherapy, 
novel agents or auto-SCT as initial therapy, 148 patients were treated with novel agent-containing 
regimens and the remaining 20 patients with conventional chemotherapy alone as salvage therapy. 
The median survival from the time of relapse was significantly extended in the novel agent group 
(45.5 months) compared with the chemotherapy group (15.0 months, p < 0.04; fig. 3b). No patient 
was treated with auto-SCT as salvage therapy. 
 
 
Fig. 3. Efficacy of novel agents on OS. a OS of patients treated with at least one novel agent-containing 
regimen during the clinical course. b Survival after relapse for relapsed patients treated with either 
conventional chemotherapy or novel agents as salvage therapy. 
 
Outcome according to Response 
The best response to treatment in the 318 patients was a complete response (CR) in 26 patients 
(8.2%), very good partial response (VGPR) in 56 (17.6%), partial response (PR) in 127 (39.9%), 
stable disease in 92 (28.9%) and disease progression in 17 (5.3%). Achievement of CR or VGPR 
was mostly observed in patients treated with auto-SCT (table 1). A significant difference in OS was 
found between the CR and PR groups (p < 0.003) and between the VGPR and PR groups (p < 0.05; 
fig. 4).  
 Fig. 4. Outcome according to response. OS according to best response, i.e. CR, VGPR, PR, stable disease (SD) 
or progressive disease (PD). 
 
Multivariate Analysis 
Finally, we performed a multivariate analysis to identify predictors independently associated with 
OS by using the Cox proportional hazards model. Variables included in the analysis were baseline 
patient factors (age, gender and type of M protein), prognostic factors (albumin, β2-microglobulin 
and ISS stage) and treatment-related factors (the use of novel agents and auto-SCT). In this 
analysis, serum albumin (p < 0.00005) and β2-microglobulin (p < 0.02) were important prognostic 
factors for OS (table 2). As for the type of M protein, the BJP type (p < 0.01) was found to be a 
significant prognostic factor associated with poor OS. Among treatment-related factors, the use of 
novel agents (p < 0.003) was an independent favorable predictor significantly associated with 
extended OS. 




In this study, we performed a retrospective analysis of the prognosis of newly diagnosed MM 
patients aged 65-70 years. We evaluated an unselected group of patients who had been treated 
between January 1, 2004, and December 31, 2009. During this period, novel agents such as 
thalidomide, lenalidomide and bortezomib were available in clinical trials and routine practice. 
Therefore, this survey allowed us to compare the difference in outcome in terms of the use of novel 
agents. 
Our data have shown that front-line therapy with novel agents or auto-SCT significantly prolonged 
OS when compared with conventional chemotherapy alone and that the use of novel agents 
followed by auto-SCT consolidation further improved OS. The additional use of novel agents as 
salvage therapy also prolonged the survival period after relapse. These findings suggest that 
treatment with novel agents and auto-SCT were effective approaches in this subgroup of MM 
patients. 
In the current study, treatment for each patient was determined by the corresponding physician, and 
the baseline patient characteristics were different between each treatment group according to initial 
therapy. Therefore, the results cannot be compared equally across the groups. At that time, novel 
agents, especially bortezomib, were not used in vulnerable patients with performance status ≥3 
because of the possibility of severe adverse events such as interstitial pneumonitis [13]. Thus, there 
was a bias in the patient background; that is, the conventional chemotherapy group included more 
fragile patients compared with the novel agent-containing regimen group or the auto-SCT group. 
Nevertheless, the median PFS in the conventional chemotherapy group was 19.1 months, which is 
similar to the previous data observed in clinical trials of melphalan + prednisone or other 
conventional chemotherapy (approximately 18 months) [14]. This suggests that the treatment 
outcome in the conventional chemotherapy group was not inferior to that in the historical standard 
chemotherapy group. Taken together, our results rather indicate a possible survival benefit of novel 
agents and auto-SCT in particular eligible patients. 
We also found that the median OS in the conventional chemotherapy group (46.0 months) was 
longer than that in previous clinical trials (29 months) [14]. This is most likely due to the 
improvement of salvage therapy with novel agents. In fact, the survival after relapse was 
significantly improved by novel agent-containing regimens compared with conventional 
chemotherapy alone regardless of the use of novel agents as initial therapy. These findings also 
support the efficacy of novel agents as salvage therapy in MM. 
Auto-SCT has been mostly applied to younger patients aged 65 or younger. Nevertheless, in this 
survey, 38 of 318 patients (12%) aged 65-70 years had been successfully managed with auto-SCT 
without transplantation-related mortality. Our results suggest that auto-SCT is a safe and effective 
approach for eligible patients with a good health condition, and this transplant eligibility in the 
elderly population is another prognostic factor for extended OS. Thus, auto-SCT is still an 
important strategy for so-called transplant-ineligible patients, as was reported previously [7,9]. 
Recent treatment strategies with novel agents have significantly improved response rates in both 
younger and elderly patients with MM [15,16,17,18]. The achievement of CR and VGPR has been 
shown to be associated with prolonged PFS and OS in both transplant-eligible and -ineligible 
patients [3,4]. In this study, CR and VGPR were mostly observed in the groups of patients treated 
with novel agents and/or auto-SCT, and these patients exhibited significantly longer OS compared 
with those achieving PR or inferior responses. Thus, the achievement of CR or VGPR was another 
favorable factor associated with extended OS, regardless of initial therapy. 
By multivariate analysis, we confirmed that serum albumin and β2-microglobulin were independent 
prognostic factors for OS. Among the types of M protein, the BJP type was related to a poor 
prognosis. The reason is probably because most patients with BJP type had the complication of 
renal damage. As for the treatment, the use of novel agents was an independent favorable 
prognostic factor associated with extended OS. Treatment with auto-SCT was not a significant 
prognostic factor, probably due to the small number of patients treated with auto-SCT. 
In conclusion, our results indicate that treatment with novel agents and auto-SCT had a major 
impact on OS in eligible patients aged 65-70 years. We should evaluate the possible clinical 
indications of using novel agents plus auto-SCT even in this subgroup of elderly patients with MM. 
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